Table 1.
Effects of nrf2 genotype on changes in mRNA levels of phase 2 enzymes after treatment with oltipraz
| Nrf2 genotype
|
||||
|---|---|---|---|---|
| +/+ | −/− | +/+ | −/− | |
| Relative
constitutive mRNA levels (vehicle/vehicle)
|
Relative
inducible mRNA levels (treated/vehicle)
|
|||
| Liver | ||||
| GST Ya | 1 | 0.61 | 4.53* | 1.25 |
| GST Yp | 1 | 0.50 | 2.66* | 1.61† |
| GST Yc | 1 | 0.92 | 1.97* | 1.10 |
| NQO1 | 1 | 0.80 | 7.64* | 1.39 |
| UDP-glucuronosyltransferase 1A6 | 1 | 1.03 | 1.34* | 1.25 |
| Microsomal epoxide hydrolase | 1 | 0.54 | 3.64* | 0.72 |
| NRF2 | 1 | ND | 3.69* | ND |
| Forestomach | ||||
| GST Ya | 1 | 0.55 | 2.04* | 0.62 |
| GST Yp | 1 | 0.31 | 1.67* | 0.26 |
| NQO1 | 1 | 0.08 | 1.68* | 0.10 |
| NRF2 | 1 | ND | 7.62* | ND |
Values are the mean of determinations on three to four mice. Levels of liver and forestomach mRNA for each gene were normalized to albumin and GAPDH mRNA levels, respectively, and expressed as a ratio to vehicle-treated, wild-type control. Transcript levels were measured 24 h after oltipraz treatment (500 mg/kg). ND, not detectable. *, P < 0.05, compared with vehicle-treated wild-type mice. †, P < 0.05, compared with vehicle-treated nrf2-deficient mice.